As of 2025-07-15, the EV/EBITDA ratio of Evoke Pharma Inc (EVOK) is 0.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EVOK's latest enterprise value is -4.16 mil USD. EVOK's TTM EBITDA according to its financial statements is -5.00 mil USD. Dividing these 2 quantities gives us the above EVOK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.2x - 9.4x | 8.0x |
| Forward P/E multiples | 9.1x - 17.5x | 13.1x |
| Fair Price | (56.42) - (58.05) | (67.05) |
| Upside | -1199.8% - -1231.5% | -1407.0% |
| Date | EV/EBITDA |
| 2025-07-11 | 0.71 |
| 2025-07-10 | 0.70 |
| 2025-07-09 | 0.58 |
| 2025-07-08 | 1.16 |
| 2025-07-07 | 1.17 |
| 2025-07-03 | 1.16 |
| 2025-07-02 | 1.16 |
| 2025-07-01 | 1.16 |
| 2025-06-30 | 1.17 |
| 2025-06-27 | 1.17 |
| 2025-06-26 | 1.17 |
| 2025-06-25 | 1.14 |
| 2025-06-24 | 1.15 |
| 2025-06-23 | 1.19 |
| 2025-06-20 | 1.15 |
| 2025-06-18 | 1.16 |
| 2025-06-17 | 1.15 |
| 2025-06-16 | 1.13 |
| 2025-06-13 | 1.13 |
| 2025-06-12 | 1.13 |
| 2025-06-11 | 1.12 |
| 2025-06-10 | 1.14 |
| 2025-06-09 | 1.12 |
| 2025-06-06 | 1.13 |
| 2025-06-05 | 1.06 |
| 2025-06-04 | 1.05 |
| 2025-06-03 | 1.04 |
| 2025-06-02 | 1.04 |
| 2025-05-30 | 1.04 |
| 2025-05-29 | 1.04 |
| 2025-05-28 | 1.05 |
| 2025-05-27 | 1.01 |
| 2025-05-23 | 1.02 |
| 2025-05-22 | 1.02 |
| 2025-05-21 | 1.06 |
| 2025-05-20 | 1.09 |
| 2025-05-19 | 1.09 |
| 2025-05-16 | 1.09 |
| 2025-05-15 | 1.09 |
| 2025-05-14 | 1.10 |
| 2025-05-13 | 1.10 |
| 2025-05-12 | 1.10 |
| 2025-05-09 | 1.10 |
| 2025-05-08 | 1.09 |
| 2025-05-07 | 1.10 |
| 2025-05-06 | 1.08 |
| 2025-05-05 | 1.11 |
| 2025-05-02 | 1.11 |
| 2025-05-01 | 1.13 |
| 2025-04-30 | 1.15 |